|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-10-25
|
|
pubmed:abstractText |
Doxorubicin (Dox) is one of the most useful chemotherapeutic agents for patients with advanced neuroblastoma (NB). A series of Dox analogs with bulky substitutions at the C-4' at amino-sugar have been designed to impair interactions between the drug and P-glycoprotein (P-gp), a multidrug drug resistance (MDR) transporter. Two analogs, WP744 and WP769, were selected and their biological properties were compared with Dox and the daunorubicin-based bisintercalator WP631. These novel Dox analogs may have antitumor activity beyond MDR evasion.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0022-4804
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2004 Elsevier Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
121
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
187-96
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15501458-Anthracyclines,
pubmed-meshheading:15501458-Apoptosis,
pubmed-meshheading:15501458-Cell Division,
pubmed-meshheading:15501458-Cell Line, Tumor,
pubmed-meshheading:15501458-Cell Survival,
pubmed-meshheading:15501458-Drug Screening Assays, Antitumor,
pubmed-meshheading:15501458-Drug Synergism,
pubmed-meshheading:15501458-Humans,
pubmed-meshheading:15501458-Neuroblastoma,
pubmed-meshheading:15501458-Nuclear Proteins,
pubmed-meshheading:15501458-Oncogene Proteins,
pubmed-meshheading:15501458-P-Glycoprotein
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
WP744 is a novel anthracycline with enhanced activity against neuroblastoma.
|
|
pubmed:affiliation |
Children's Hospital Research Foundation, Department of Pediatric Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. thomas.inge@cchmc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
